亞盛醫藥：新藥利沙托克拉獲中國NMPA附條件批准上市

華爾街見聞

07/10

亞盛醫藥（06855）公告要點解讀核心事件新藥獲批上市：公司自主研發的新型Bcl-2抑制劑利沙托克拉（利生妥）獲中國NMPA附條件批准上市，成爲中國首個上市用於治療CLL/SLL的Bcl-2抑制劑，全球第二個上市的同類藥物。關鍵要點適應症：用於治療既往經過至少包含BTK抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者臨牀數據：基於關鍵註冊II期臨牀研究結果...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550617943"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550617943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550617943?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-10 17:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550617943","market":"us","top_or_hot":-1,"title":"亞盛醫藥：新藥利沙托克拉獲中國NMPA附條件批准上市","media":"華爾街見聞","content":"<div>\n<p>亞盛醫藥（06855）公告要點解讀核心事件新藥獲批上市：公司自主研發的新型Bcl-2抑制劑利沙托克拉（利生妥）獲中國NMPA附條件批准上市，成爲中國首個上市用於治療CLL/SLL的Bcl-2抑制劑，全球第二個上市的同類藥物。關鍵要點適應症：用於治療既往經過至少包含BTK抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者臨牀數據：基於關鍵註冊II期臨牀研究結果...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亞盛醫藥：新藥利沙托克拉獲中國NMPA附條件批准上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亞盛醫藥：新藥利沙托克拉獲中國NMPA附條件批准上市\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">華爾街見聞</strong><span class=\"h-time small\">2025-07-10 17:01</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>亞盛醫藥（06855）公告要點解讀核心事件新藥獲批上市：公司自主研發的新型Bcl-2抑制劑利沙托克拉（利生妥）獲中國NMPA附條件批准上市，成爲中國首個上市用於治療CLL/SLL的Bcl-2抑制劑，全球第二個上市的同類藥物。關鍵要點適應症：用於治療既往經過至少包含BTK抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者臨牀數據：基於關鍵註冊II期臨牀研究結果...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b\">華爾街見聞</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AAPG","symbol_name":"亞盛醫藥","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","article_id":"2550617943","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550617943","pubTimestamp":1752138081,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"亞盛醫藥公告要點解讀核心事件新藥獲批上市：公司自主研發的新型Bcl-2抑制劑利沙托克拉（利生妥）獲中國NMPA附條件批准上市，成為中國首個上市用於治療CLL/SLL的Bcl-2抑制劑，全球第二個上市的同類藥物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AAPG":"亚盛医药","BK4139":"生物科技"},"translate_title":"Ascentage Pharma: The new drug Lisatocla was conditionally approved by China's NMPA for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAPG":1},"content_text":"亞盛醫藥（06855）公告要點解讀核心事件新藥獲批上市：公司自主研發的新型Bcl-2抑制劑利沙托克拉（利生妥）獲中國NMPA附條件批准上市，成為中國首個上市用於治療CLL/SLL的Bcl-2抑制劑，全球第二個上市的同類藥物。關鍵要點適應症：用於治療既往經過至少包含BTK抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者臨牀數據：基於關鍵註冊II期臨牀研究結果獲批，ORR達到預設研究終點，未發生腫瘤溶解綜合徵副作用，血液學毒性發生率低且程度可控在研管線：目前正開展四項全球註冊III期臨牀研究，包括GLORA、GLORA-2、GLORA-3、GLORA-4研究商業化意義：這是公司繼耐立克後第二個獲批上市的原創新藥，標誌着公司商業化能力進一步提升","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}